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Bortezomib, a proteasome inhibitor capable of direct antitumor effects, has been shown to prevent acute
graft-versus-host disease (GVHD) when administered in a short course immediately after bone marrow
transplantation (BMT) in mice. However, when bortezomib is given continuously, CD4þ T cellemediated
gastrointestinal tract damage increases GVHD mortality. To investigate the protective effects of bortezomib on
other organs, we used a CD8-dependent acute GVHD (aGVHD) model of C3H.SW donor T cells engrafted into
irradiated C57BL/6 recipients (minor MHC mismatch), which lack signiﬁcant gut GVHD. Our data in this
model show that bortezomib can be given continuously to prevent and treat aGVHD mediated by CD8þ T cells,
but this effect is organ speciﬁc, such that only skin, and not liver, protection was observed. Despite the lack of
hepatic protection, bortezomib still signiﬁcantly improved survival, primarily because of its skin protection.
Reduced skin GVHD by bortezomib was correlated with reduced serum and skin IL-6 levels. Administration of
a blocking IL-6 antibody in this model also resulted in similar cutaneous GVHD protection. These results
indicate that bortezomib or blockade of IL-6 may prevent CD8þ T cellemediated cutaneous acute GVHD.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION can indirectly lead to priming, activation, and differentiation
Graft-versus-host disease (GVHD) has severely limited
the use of allogeneic hematopoietic stem cell transplantation
(allo-HSCT) for the treatment of hematological malignancies
[1]. Donor T cellemediated alloreactive responses and con-
ditioning regimeneinduced tissue damage, with subsequent
activation of the innate immune system and inﬂammatory
cytokine release, are implicated in the pathogenesis of acute
GVHD (aGVHD) after allo-HSCT [2,3].
Cytokines, such as TNF-a, can augment aGVHD through
direct cytotoxic impact on host tissues [4]. Other proin-
ﬂammatory cytokines, including IL-1, IL-17, IL-6, and IFN-g,dgments on page 1903.
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IL-6 is a proinﬂammatory cytokine with pleiotropic
biological activities in immune regulation and inﬂammation
[6]. Murine studies [7-9] have previously demonstrated the
beneﬁt of IL-6 inhibition inGVHDmanagement. Recently, there
havebeenanecdotal clinical trials suggesting thebeneﬁtof such
an approach in a limited number of patients [10,11]. However,
with the heterogeneous presentations of aGVHD, target organs
for such beneﬁcial effects need to be better identiﬁed.
Bortezomib, a proteasome inhibitor, is routinely used for
the treatment of hematological malignancies [12]. In
addition to its direct antitumor effects, bortezomib specif-
ically depletes alloreactive T cells, permits regulatory T (Treg)
cell survival, and attenuates proinﬂammatory cytokine
responses [13-15]. Bortezomib also augments graft-versus-
tumor (GVT) responses by sensitizing tumor cells to
cytolytic effector mechanisms [16]. These effects make
proteasome inhibition an attractive therapeutic approach for
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prophylaxis of acute GVHD have demonstrated encouraging
results [17,18]. However, we have also previously shown that
bortezomib can have a time- and dose-dependent detri-
mental proinﬂammatory effect by causing a marked increase
in CD4þ Tcellemediated aGVHD and gut pathologyeinduced
lethality, resulting in early death of animals. These outcomes
have made assessment of bortezomib in other organs very
difﬁcult [19]. To investigate the protective effects of borte-
zomib on other organs, we used a CD8-dependent aGVHD
model of C3H.SW donor T cells engrafted into irradiated
C57BL/6 recipients, creating a MHC-matched, minor histo-
compatibility antigen (miHA)emismatched model, which
does not result in signiﬁcant gut GVHD pathology.
Continuous administration of bortezomib after hemato-
poietic stem cell transplantation resulted in tissue-speciﬁc
protection such that only cutaneous, but not hepatic, GVHD
was protected, and this protection was associated with
decreased IL-6 levels. IL-6 blockade had similar beneﬁcial
effects on skin but not on liver GVHD, suggesting the direct
role of IL-6 in skin GVHD pathogenesis. Furthermore,
bortezomib administration resulted in the speciﬁc down-
regulation of CXCR3, a skin-homing chemokine receptor, on
donor CD8þ T cells. These data indicate that prophylactic
bortezomib administration can induce organ-speciﬁc
protection from cutaneous acute GVHD.
MATERIALS AND METHODS
Animals
Female donor C3H.SW (H2b) and recipient C57BL/6 (H2b) mice were
purchased from Jackson Laboratory (Bar Harbor, ME). Animals were kept in
pathogen-free conditions and used at 8 to 10 weeks of age. All mice were
maintained at the UC Davis Medical Center vivarium in accordance with
Institutional Animal Care and Use Committee standards.
Allo-HSCT
Donor bone marrow cells (BM) were collected and T celledepleted bone
marrow cells (TCD-BM) were prepared using the monoclonal anti-Thy 1.2
(38H12) antibody and rabbit complement, as previously described [20].
CD8þ T cells were negatively selected from spleen cell suspensions using a
CD8 T cell isolation kit (Miltenyi Biotec, San Diego, CA). Brieﬂy, C57BL/6
(H2b) recipient mice received 950 cGy myeloablative dose of total body
irradiation (TBI) from a 137Cs source, followed by the infusion of 1.0  107
donor C3H.SW (H2b) TCD-BM intravenously, with or without 2 to 3  106
donor C3H.SWepuriﬁed CD8þ T cells. Recipient C57BL/6 mice were
randomly grouped and treated either with PBS or bortezomib in PBS at a
dose of .125 mg/kg i.p. on days 0 and 6 followed by every 5 days, for a total of
10 injections after BM transplantation (BMT). Anti-IL-6 antibody (stock:
10.47 mg/mL; CNTO1322, Centocor, Radnor, PA) or isotype control (rat
IgG2a; stock: 9.378 mg/mL; CNTO345, Centocor) was administered i.p.
(1 mg/mouse) every week starting on day 0 for a total of 10 injections after
BMT. Skin clinical score was evaluated based on previous studies [21] as
healthy appearance ¼ 0; skin lesions with alopecia less than 1 cm2 ¼ 1; skin
lesions with alopecia 1 to 2 cm2¼ 2; or skin lesions with alopecia larger than
2 cm2 in area ¼ 3. Tail, ear, and paw scaling were scored at an additional .3
point for each lesion. Mice with clinical scores over 3.3 were euthanized,
based on Institutional Animal Care and Use Committee regulations.
Reagents
Bortezomib was provided by Millennium Pharmaceuticals (Cambridge,
MA). Stock bortezomib solution (1 mg/mL) was prepared in Dulbecco’s PBS
and stored at 80C before use. AntieIL-6 antibody (stock: 10.47 mg/m;
CNTO1322) and isotype control (stock: 9.378 mg/mL; CNTO345) were pro-
vided by Centocor Inc.
Histology
Formalin-ﬁxed parafﬁneembedded tissue sections were stained with
hematoxylin and eosin and evaluated blindly and independently by 2
pathologists. A semiquantitative scale from 0 to 4 was used, where histo-
pathologic changes were identiﬁed as minimal (1), mild (2), moderate (3),
and severe (4). Images were acquired with an Olympus BX45 clinical
microscope (Olympus, Woodbury, NY) and DP72 digital camera (Diagnostic
Instruments, Sterling Heights, MI).Cytokine Analysis
Serum cytokine levels (TNF-a, IFN-g, IL-6, and IL-17) were determined
using Cytometric Bead Array (BD, San Jose, CA) with cytokine-speciﬁc bead
sets and standards according to the manufacturer’s protocol.
Quantitative Real-Time RT-PCR
Quantitative real-time RT-PCR was done by using Applied Biosystems
Cycler (AB Step-ONE Plus) with SYBR Green SuperMix (Applied Biosystems/
Life Technology, Grand Island, NY). Tissue RNA was extracted from skin
samples using a Qiagen kit (Valencia, CA) according to the Manufacturer’s
protocol. After obtaining cDNA, samples were evaluated for gene expression
levels using primers purchased from Superarray Qiagen (SABioscience,
Valencia, CA) b-actin and GADPH were used as housekeeping genes, and
relative fold change expression was calculated as follows: DDCt ¼ DCt
(experimental group) - DCt (control group). The data are presented as
relative fold change expression of each gene in comparison to TCD-BM
group.
Antibodies and Flow Cytometry
Protocols were conducted as previously described [19]. CD8a-AF700
(BioLegend, San Diego, CA), CXCR3-PE (BioLegend), CD4-PE-Cy7 (eBio-
science), Foxp3-FITC (eBioscience , San Diego, CA), and CD45-PB (BioLegend)
were used for these studies. Skin samples were prepared as previously
described [22]. Brieﬂy, single-cell suspensions (1 million cells) were ﬁrst
incubated with Fc Block (BD Pharmingen, San Diego, CA) for 10 minutes,
then coincubated with antibodies for 20 minutes at 4C, followed by
washing with staining buffer (PBS þ 1% FBS). Foxp3 intracellular staining
was performed using an eBioscience kit (catalog number 00-5523-00), ac-
cording to the manufacturer’s protocol. Flow cytometry was performed on a
LSR Fortessa (BD, San Jose, CA) and data were analyzed by FlowJo software
(TreeStar, Ashland, OR).
Statistics
Survival data was plotted by the Kaplan-Meier method and analyzed by
the log-rank test. One-way or 2-way ANOVA or Student’s t tests were
performed to determine if mean values were signiﬁcantly different (P< .05),
when appropriate.
RESULTS
Skin aGVHD in MHC-matched, miHA-mismatched Model
Is Associated with Increased Serum IL-6 Levels
In this study, a CD8-dependent aGVHDmurinemodel was
used. This is an MHC-matched, multiple miHA-mismatched
murine model in which C3H.SW donor cells are infused
into lethally irradiated C57BL/6 recipients, mimicking the
majority of marrow grafts for allo-HSCT cases seen clinically
[23]. As previously shown [8,23], infusion of TCD-BM plus
CD8þ T cells isolated from spleen result in aGVHD in skin
and/or liver with minimal gastrointestinal pathology when
compared with mice infused with TCD-BM only
(Figure 1A,B). Skin damage was particularly severe and the
primary cause of mortality in this model. Although the ma-
jority of the recipients showed combined skin and liver
aGVHD, 20% of the recipients suffered from liver-only GVHD
with variable levels of liver damage (Figure 1C). There were
no recipients with skin-only GVHD. Serum levels of TNF-a,
IFN-g, IL-17, and IL-6 were measured and the results were
compared among different GVHD pathologic groups. IL-6
serum levels correlated with skin but not with liver GVHD
occurrence, demonstrating a tissue-speciﬁc association
(Figure 1D) (72.66  18.22 versus 21.61  4.77 versus
9.88  2.26). There was no signiﬁcant difference in the level
of serum IL-6 between liver-only GVHD and TCD-BM (con-
trol) groups. Similarly, increased IL-6 expression was detec-
ted by quantitative real-time RT-PCR in the skin samples
when compared with the control group (Figure 1E) (P < .05),
but there was no change noted in liver IL-6 expression
(Figure 1F). These ﬁndings demonstrate that both systemic
and local tissue IL-6 levels are associated with skin GVHD,
but not with liver GVHD, pathology in this model.
Figure 1. Characteristics of murine GVHD in MHC-matched miHA-mismatched model. C57BL/6 recipient mice received 950 cGy myeloablative dose of TBI from a 137Cs
source. A dose of 1.0  107 donor C3H.SW TCD-BM cells was infused with or without 2 to 3  106 donor C3H.SWepuriﬁed CD8þ T cells after TBI. GVHD target samples
(gut, skin, and liver) were harvested and stained with H & E. The grading of histopathological GVHD damage in recipients that had undergone transplantation was
assessed according to the scoring system described in the Methods section. Serum samples were taken by cardiac punctures and stored for analysis. (A) Representative
histopathologic examination of H & Eestained sections of parafﬁn-embedded skin, liver, and gut tissues. Arrows indicate erosion of epidermis with inﬂammatory
inﬁltrate in the skin and arrowheads indicate marked inﬂammatory inﬁltration over portal triads in the liver. (B) Semiquantitative histologic grading (grade 0 to 4) of
different target tissues. (C) Liver pathology scores were graded from 1 to 4 and were shown as percentage between skin and liver GVHD and liver GVHD only groups. (D)
Serum IL-6 level was examined in skin and liver GVHD, compared with liver only or TCD-BM only groups. (E) Relative RNA expression of IL-6 levels in the skin. (F) Relative
RNA expression of IL-6 levels in the liver. All the data were collected from 2 or 3 independent experiments with at least 8 mice (n ¼ 8) per group. Data were analyzed by
1-way ANOVA or Student’s t-tests to determine if mean values were signiﬁcantly different. P < .05 (*), P < .001 (***), P < .0001 (****) were considered signiﬁcant.
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but not Hepatic, GVHD and Correlates with Decreased
IL-6 Levels
Donor BM cells plus CD8þ T cells from C3H.SW were
adoptively transferred into C57BL/6 mice. Mice were ran-
domized to receive either bortezomib or vehicle. We
observed a signiﬁcant decrease in the occurrence of skin
aGVHD with bortezomib compared with the vehicle group
(Figure 2A,B) without any differential decline in body weight
(Figure 2C). Pathological examination further documented a
tissue-speciﬁc protection effect of bortezomib in skin but not
liver GVHD (Figure 2D-F). Although the TCD-BM and CD8
T cell groups exhibited multifocal necrosis and T cell inﬁl-
tration in the epidermal and dermal areas of the skin,
treatment with bortezomib did not substantially decrease
the T cell inﬁltrate in the liver. Additionally, liver enzyme
levels concurred with histopathology scoring, showing no
effects on liver pathology with bortezomib treatment
(Figure 2G). Serum IL-6 levels were signiﬁcantly reduced by
bortezomib treatment (Figure 2H), supporting that the skin-
speciﬁc protective effect of bortezomib correlated with a
reduction in serum IL-6 levels.Anti-IL-6 Therapy Provides Similar Skin, but not Liver,
GVHD Protection
To ascertain if IL-6 is indeed a target in cutaneous aGVHD
pathogenesis or simply a surrogate of tissue inﬂammation
and damage, similar experiments were done with weekly
administration of antieIL-6 monoclonal antibody after HSCT.AntieIL-6 treatment signiﬁcantly decreased the severity of
skin GVHD but had no protective effect on liver pathology
(Figure 3A) or serum liver enzyme levels (Figure 3B)
compared with the group that received an isotype control
antibody. Both bortezomib and antieIL-6 treatments led to a
reduction in skin IL-6 gene expression (Figure 3C). It has been
shown previously that IL-6 increases T cell trafﬁcking to
target tissues by augmenting chemokine expression levels in
skin [24,25]. Both bortezomib and antieIL-6 therapy reduced
donor-derived CD8þ T cell inﬁltration in the skin tissues
(Figure 3D,E). CD8þCXCR3þ T cells from splenocytes were
also reduced after bortezomib treatment compared with the
GVHD control group (Figure 3F,G), indicating a potential
mechanism for bortezomib on the tissue-speciﬁc protection
of skin GVHD. In addition, IL-6 blockade has been shown to
induce Treg cells after BMT [7]. Here, we also observed an
increase in Treg cells with antieIL-6 therapy compared with
isotype controls (Figure 3H). The protective effects of both
bortezomib and antieIL-6 therapy further provided signiﬁ-
cant survival beneﬁt compared with the GVHD group
(Figure 3I), supporting the role of IL-6 in mediating GVHD
pathogenesis.DISCUSSION
We and others have shown protective effects of bortezo-
mib administration in major MHC-mismatched models
when unselected T cell populations were used as a means to
prevent aGVHD [26]. However, continuous treatment of
bortezomib resulted in marked increases in GVHD mortality
Figure 2. Tissue-speciﬁc protection by continuous application of bortezomib with decreased skin, but not liver, GVHD is associated with serum IL-6 level. C57BL/6
recipient mice received 950 cGy myeloablative dose of TBI from a 137Cs source. A dose of 1.0  107 donor C3H.SW BM cells was infused with or without 2 to 3  106
donor C3H.SW-puriﬁed CD8þ T cells after TBI. Recipient C57BL/6 mice then received PBS or bortezomib at a dose of .125 mg/kg i.p. after BMT. (A) Representative
clinical pictures of skin GVHD. (B) Skin clinical scores were evaluated twice a week. (C) Body weight changes among different groups. (D) Representative H & E stained
sections of parafﬁn-embedded skin and liver from recipients. Arrows indicate erosion of epidermis with inﬂammation inﬁltrate. Arrowheads indicate inﬂammatory
inﬁltration over portal triads in the liver. (E-F) Semiquantitative histological analysis (grade 0 to 4) of at least 6 examined recipients in each organ. (G) Liver enzymes
from recipients with or without bortezomib therapy and TCD-BM control groups. (H) Serum IL-6 levels of recipients with or without bortezomib therapy were
analyzed. All the data were collected from 2 independent experiments with at least 6 mice (n ¼ 6) per group. Data were analyzed by 1-way ANOVA and post-hoc
Tukey test to determine if mean values were signiﬁcant among groups. P < .05 (*) and P < .01(**) were considered signiﬁcant.
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severe toxicity and its associated early mortality prevented
us from better understanding the effects of bortezomib on
other GVHD target organs. The current study demonstrates
that continuous bortezomib treatment can be safely admin-
istered in models where CD8þ T cells are the primary me-
diators of GVHD and this treatment results in the selective
protection of skin GVHD. Furthermore, our study highlights
the role of IL-6 in mediating skin aGVHD as well as its po-
tential as a biomarker of response to bortezomib treatment
of skin aGVHD. Our data on IL-6 inhibition further support
that IL-6 may have a mechanistic effect in skin pathology, as
previously suggested [9], rather than solely being a
biomarker for tissue injury and inﬂammation. It has also
been demonstrated that macrophages are 1 of the main
sources for IL-6 secretion, and inhibiting macrophage acti-
vation can successfully abrogate skin GVHD in aGVHD
models [28]. Therefore, it is likely that bortezomib, as an
inhibitor of NF-kb, can directly affect macrophage activation
and prevent cutaneous GVHD lesions. Binding of IL-6 to its
receptors on endothelial cells can trigger trans-signaling and
activate the signal transducer and activator of transcription-3
pathway [29], resulting in chemokine expression and T cellrecruitment [24,30]. In our experiments, decreased homing
of CD8þ T cells to skin after antieIL-6 therapy suggests a
potential role of IL-6 in the homing of these T cells, although
further experiments are required to prove this concept. In
addition, we have also shown that the reduction of IL-6 can
enhance Treg cells during donor T cell reconstitution, aiding
in the further protection from the destructive inﬂammatory
response to engraftment.
The concept of organ-speciﬁc pathological mechanisms in
GVHD has recently been re-evaluated. Chemokines and their
receptors can be 1 of the explanations for the diversity of
pathological changes in GVHD. CXCL10/CXCR3 axis has been
shown to play a pivotal role in skin aGVHD responses after
allo-HSCT [31]. In our experiments, bortezomib treatment
resulted in a reduction of skin homing of CXCR3þCD8þ Tcells,
which likely contributes to its skin-speciﬁc protection ef-
fects. In addition, IL-6 has been shown to speciﬁcally
decrease CXCL10, a chemokine ligand for CXCR3, suggesting
that bortezomib’s effects on homing of T cells can be exerted
through the IL-6-CXCL10-CXCR3 axis. Regarding T cell traf-
ﬁcking into the liver, it has been previously demonstrated
that CCR2 is required for CD8 T cell migration into the liver
and the gastrointestinal tract, but not into skin, in an acute
Figure 3. AntieIL-6 therapy in skin GVHD model. C57BL/6 recipient mice received 950 cGy TBI and underwent transplantation with TCD-BM with or without
puriﬁed CD8þ T cells. AntieIL-6 antibody or isotype control was given at a dose of 1 mg/mouse i.p. after BMT and every week thereafter. (A) Representative
histopathologic scores were examined from parafﬁn-embedded skin and liver from recipients with or without antieIL-6 therapy and TCD-BM control groups. (B)
Liver enzymes from recipients with or without antieIL-6 therapy and TCD-BM control groups. (C) Skin tissues were analyzed for IL-6 expression levels by qRT-PCR.
(D) Skin samples were harvested and digested into single cell suspension for ﬂow cytometry analysis. (E) Total numbers of CD45þCD8þ T cell in the skin tissues. (F)
CD45þCD8þCXCR3þ T cells in spleen after BMT with different treatments. (G) Total numbers of CD45þCD8þCXCR3þ T cells in spleen. (H) Total numbers of Treg cells
were determined by ﬂow cytometry in skin. (I) Survival curve among different treatment groups. All the data were collected from 2 to 3 independent experiments
with at least 5 mice (n ¼ 5) per group. Data were analyzed by 1-way ANOVA with post-hoc Tukey test. Survival curves were pooled from 2 to 3 independent
experiments with 14 to 18 mice per group and plotted by the Kaplan-Meier method and analyzed by the log-rank test. P < .05 (*), P < .01 (**), P < .001 (***) were
considered signiﬁcant.
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bind to CCL2, and CCL2 is induced by IFN-g and TNF-a [33].
We did not see a difference of IFN-g and TNF-a (data not
shown) with or without bortezomib treatment, in line with
the lack of effects noted in liver pathology in our murine
model. It is likely that bortezomib only affects certain che-
mokines that contribute to preferential target organ protec-
tion. It will be important for future clinical trials to
investigate whether bortezomib has skin-speciﬁc protective
effects for select GVHD patients.
The pathology seen in GVHD in response to bortezomib
also reveals a possible dose-dependent characteristic of
proteasome inhibition. Although the higher dose of borte-
zomib treatment (.625 mg/kg mouse) in this model led to
early mortality (data not shown), lower doses (.125 mg/kg)
protected mice from GVHD pathogenesis. This suggests that
the therapeutic index for bortezomib in allogeneic BMTgiven
early after BMT is narrow, and appropriate caution should be
exercised with regards to the beneﬁts and risks of bortezo-
mib treatment.
Recent clinical trials of bortezomib [17,18] or antieIL-6
receptor monoclonal antibody treatment (tocilizumab) [11]have demonstrated promising results in the management
of aGVHD, but such results require further dissection before
larger clinical trials can be initiated. The animal model used
in our current study can help improve future translational
research in this area. The results of this study can increase
our understanding of tissue-speciﬁc GVHD pathology with
an additive implication of appropriate GVHD patient popu-
lation selection for bortezomib and/or antieIL-6 therapy in
clinical trials.ACKNOWLEDGMENTS
The authors thank Monja Metcalf and Weihong Ma
for technical help and useful advice. This work has been
supported by National Cancer Institute (NCI) grant
R01CA102282.
Financial disclosure: M.A. received Material Transfer
Agreement from Millennium Company.
Authorship statement: C.P. and H.H. contributed equally as
ﬁrst authors. M.A. and W.J.M. contributed equally as senior
authors.
C.-C.S. Pai et al. / Biol Blood Marrow Transplant 20 (2014) 1899e19041904REFERENCES
1. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol. 2007;7:
340-352.
2. Das R, Komorowski R, Hessner MJ, et al. Blockade of interleukin-23
signaling results in targeted protection of the colon and allows for
separation of graft-versus-host and graft-versus-leukemia responses.
Blood. 2010;115:5249-5258.
3. Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic he-
matopoietic stem cell transplantation. Ann Rev Immunol. 2007;25:
139-170.
4. Levine JE. Implications of TNF-alpha in the pathogenesis and man-
agement of GVHD. Int J Hematol. 2011;93:571-577.
5. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease
biology and therapy. Nat Rev Immunol. 2012;12:443-458.
6. Kishimoto T. IL-6: from its discovery to clinical applications. Int
Immunol. 2010;22:347-352.
7. Chen X, Das R, Komorowski R, et al. Blockade of interleukin-6 signaling
augments regulatory T-cell reconstitution and attenuates the severity
of graft-versus-host disease. Blood. 2009;114:891-900.
8. Tawara I, Koyama M, Liu C, et al. Interleukin-6 modulates graft-versus-
host responses after experimental allogeneic bone marrow trans-
plantation. Clin Cancer Res. 2011;17:77-88.
9. Le Huu D, Matsushita T, Jin G, et al. IL-6 blockade attenuates the
development of murine sclerodermatous chronic graft-versus-host
disease. J Invest Dermatol. 2012;132:2752-2761.
10. Gergis U, Arnason J, Yantiss R, et al. Effectiveness and safety of tocili-
zumab, an anti-interleukin-6 receptor monoclonal antibody, in a pa-
tient with refractory GI graft-versus-host disease. J Clin Oncol. 2010;28:
e602-604.
11. Drobyski WR, Pasquini M, Kovatovic K, et al. Tocilizumab for the
treatment of steroid refractory graft-versus-host disease. Biol Blood
Marrow Transplant. 2011;17:1862-1868.
12. Moreau P, Richardson PG, Cavo M, et al. Proteasome inhibitors in
multiple myeloma: 10 years later. Blood. 2012;120:947-959.
13. Tung D, Cheung PH, Kaur P, et al. Anti-inﬂammatory and immuno-
modulatory effects of bortezomib in various in vivo models. Pharma-
cology. 2011;88:100-113.
14. Cullen SJ, Ponnappan S, Ponnappan U. Proteasome inhibition up-
regulates inﬂammatory gene transcription induced by an atypical
pathway of NF-kappaB activation. Biochem Pharmacol. 2010;79:
706-714.
15. Blanco B, Perez-Simon JA, Sanchez-Abarca LI, et al. Treatment with
bortezomib of human CD4þ T cells preserves natural regulatory T cells
and allows the emergence of a distinct suppressor T-cell population.
Haematologica. 2009;94:975-983.
16. Ames E, Hallett WH, Murphy WJ. Sensitization of human breast cancer
cells to natural killer cell-mediated cytotoxicity by proteasome inhi-
bition. Clin Exp Immunol. 2009;155:504-513.
17. Koreth J, Stevenson KE, Kim HT, et al. Bortezomib-based graft-versus-
host disease prophylaxis in HLA-mismatched unrelated donor trans-
plantation. J Clin Oncol. 2012;30:3202-3208.18. Koreth J, Stevenson KE, Kim HT, et al. Bortezomib, tacrolimus, and
methotrexate for prophylaxis of graft-versus-host disease after
reduced-intensity conditioning allogeneic stem cell transplantation
from HLA-mismatched unrelated donors. Blood. 2009;114:3956-3959.
19. Sun K, Wilkins DE, Anver MR, et al. Differential effects of proteasome
inhibition by bortezomib on murine acute graft-versus-host disease
(GVHD): delayed administration of bortezomib results in increased
GVHD-dependent gastrointestinal toxicity. Blood. 2005;106:3293-3299.
20. Sun K, Hsiao HH, Li M, et al. IFN-gamma receptor-deﬁcient donor T
cells mediate protection from graft-versus-host disease and preserve
graft-versus-tumor responses after allogeneic bone marrow trans-
plantation. J Immunol. 2012;189:2033-2042.
21. Anderson BE, McNiff JM, Matte C, et al. Recipient CD4þ T cells that
survive irradiation regulate chronic graft-versus-host disease. Blood.
2004;104:1565-1573.
22. Ginhoux F, Collin MP, Bogunovic M, et al. Blood-derived dermal
langerinþ dendritic cells survey the skin in the steady state. J Exp Med.
2007;204:3133-3146.
23. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus
host disease by inactivation of host antigen-presenting cells. Science.
1999;285:412-415.
24. Jones SA. Directing transition from innate to acquired immunity:
deﬁning a role for IL-6. J Immunol. 2005;175:3463-3468.
25. McLoughlin RM, Jenkins BJ, Grail D, et al. IL-6 trans-signaling via STAT3
directs T cell inﬁltration in acute inﬂammation. Proc Natl Acad Sci U S A.
2005;102:9589-9594.
26. Sun K, Welniak LA, Panoskaltsis-Mortari A, et al. Inhibition of acute
graft-versus-host disease with retention of graft-versus-tumor effects
by the proteasome inhibitor bortezomib. Proc Natl Acad Sci U S A. 2004;
101:8120-8125.
27. Sun K, Li M, Sayers TJ, et al. Differential effects of donor T-cell cytokines
on outcome with continuous bortezomib administration after alloge-
neic bone marrow transplantation. Blood. 2008;112:1522-1529.
28. Nishiwaki S, Nakayama T, Murata M, et al. Dexamethasone Palmitate
Ameliorates Macrophages-Rich Graft-versus-Host Disease by Inhibiting
Macrophage Functions. PloS One. 2014;9:e96252.
29. Fielding CA, Jones GW, McLoughlin RM, et al. Interleukin-6 signaling
drives ﬁbrosis in unresolved inﬂammation. Immunity. 2014;40:40-50.
30. Hurst SM, Wilkinson TS, McLoughlin RM, et al. Il-6 and its soluble re-
ceptor orchestrate a temporal switch in the pattern of leukocyte
recruitment seen during acute inﬂammation. Immunity. 2001;14:
705-714.
31. Piper KP, Horlock C, Curnow SJ, et al. CXCL10-CXCR3 interactions play
an important role in the pathogenesis of acute graft-versus-host dis-
ease in the skin following allogeneic stem-cell transplantation. Blood.
2007;110:3827-3832.
32. Terwey TH, Kim TD, Kochman AA, et al. CCR2 is required for CD8-
induced graft-versus-host disease. Blood. 2005;106:3322-3330.
33. Ichiba T, Teshima T, Kuick R, et al. Early changes in gene expression
proﬁles of hepatic GVHD uncovered by oligonucleotide microarrays.
Blood. 2003;102:763-771.
